RESEARCH PAPER

eMedica-Electromagnetic Cell Current Modulation Approach in the Management of Oral Health Complications in Diabetes Mellitus

Dr Rohit Kumar Singh[1], Dr Harikrishna Reddy[2], Dr Deepak Nagpal[3*], Dr Akhil Girdhar [3], Dr Apsara [3], Hemant Rohera [4]

[1*]Department of Prosthodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai - 600077, TN, India
[2] Department of Periodontics, Government Dental College Hyderabad, 500012
[3]Department of Oral Pathology and Microbiology, Maharishi Markandeshwar College of Dental Sciences and Research, Mullana, Haryana, 133203
[4] Rohera Healthcare technologies Pvt Ltd, Pune 411040
***Corresponding Author:**Dr. Deepak Nagpal
Email: deepaknagpal2013@gmail.com

Abstract
Background: Diabetes mellitus is a chronic metabolic disorder with well-documented systemic and oral complications. Among these, periodontal disease represents one of the most prevalent and severe manifestations, driven by persistent hyperglycemia, altered immune response, and increased inflammatory burden. Conventional therapeutic approaches often fail to achieve optimal outcomes due to inadequate drug concentration at the target site and rapid clearance from the oral environment.
Objective: To evaluate the efficacy of an eMedica-based targeted oral drug delivery system in improving clinical and microbiological parameters in patients with type 2 diabetes mellitus presenting with periodontal disease.
Methods:A randomized, parallel-group clinical trial was conducted on 60 patients diagnosed with type 2 diabetes mellitus. Participants were divided into two groups: Group A (control) receiving conventional periodontal therapy and Group B (test) receiving eMedica-assisted localized drug delivery. Clinical parameters including Gingival Index (GI), Periodontal Pocket Depth (PPD), salivary glucose levels, and microbial colony count were assessed at baseline, 1 month, and 3 months. Statistical analysis was performed using paired and unpaired t-tests with significance set at $p < 0.05$.
Results: Group B demonstrated statistically significant improvements compared to Group A. Reduction in gingival inflammation (GI: 0.9 ± 0.1 vs 1.6 ± 0.2), greater pocket depth reduction (2.3 mm vs 1.2 mm), and enhanced microbial load reduction (65% vs 35%) were observed. Salivary glucose levels also showed a notable decrease in the test group, indicating improved local metabolic control.
Conclusion: The eMedica-based targeted drug delivery system significantly enhances therapeutic outcomes in diabetic patients with periodontal disease. Its ability to provide localized, controlled, and glucose-responsive drug release offers a promising advancement in precision oral healthcare.
Keywords: Diabetes mellitus, eMedica, targeted drug delivery, periodontal disease, localized therapy, oral health

How To Cite This Article: Singh Rk, Reddy H, Nagpal D, Girdhar A, Apsara, Rohera H. Emedica-Electromagnetic Cell Current Modulation Approach In The Management Of Oral Health Complications In Diabetes Mellitus. Int J Drug Deliv Technol. 2026;16(27s):974-982. Doi: 10.25258/ijddt.16.27s.113

Introduction

Diabetes mellitus is a complex, chronic metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. It is a major global health concern, with rapidly increasing prevalence and associated morbidity[1-5]. The systemic complications of diabetes are well established, affecting multiple organ systems including cardiovascular, renal, neurological, and ocular tissues. In addition to these systemic effects, diabetes exerts a profound influence on oral health, making it a critical area of concern in dental and periodontal research[6-10].

Among the various oral manifestations, periodontal disease is considered the sixth complication of diabetes. The relationship between diabetes and periodontal disease is bidirectional and synergistic[11-15]. Chronic hyperglycemia leads to the formation of advanced glycation end products (AGEs), which interact with their receptors (RAGE) on host cells, triggering an exaggerated inflammatory response. This results in increased production of pro-inflammatory cytokines such as interleukin-1β, tumor necrosis factor-α, and prostaglandins, ultimately contributing to periodontal tissue destruction. Additionally, diabetes impairs neutrophil function, alters collagen metabolism, and compromises wound healing, further exacerbating periodontal breakdown[16-20].

Conversely, periodontal inflammation negatively impacts glycemic control by increasing systemic

inflammatory mediators, thereby contributing to insulin resistance. This bidirectional relationship highlights the importance of effective periodontal management in diabetic patients, not only for oral health but also for overall metabolic control[21-25].

Traditional periodontal therapies, including scaling and root planing combined with systemic or local antimicrobial agents, have shown limited success in diabetic individuals. One of the primary challenges is the inability to maintain therapeutic drug concentrations at the site of infection due to rapid salivary clearance, enzymatic degradation, and poor retention in periodontal pockets. Systemic drug administration, while useful, is often associated with side effects and reduced patient compliance, particularly in long-term management[26-31].

In recent years, advancements in drug delivery systems have shifted focus toward localized, controlled-release formulations that can provide sustained therapeutic effects directly at the site of pathology. These systems enhance drug bioavailability, reduce systemic exposure, and improve clinical outcomes. However, conventional localized delivery systems still lack adaptability to dynamic physiological conditions such as fluctuating glucose levels in diabetic patients[32-37].The emergence of eMedica technology represents a significant advancement in this domain. eMedica integrates smart drug delivery mechanisms with real-time physiological responsiveness, enabling precision-based therapeutic interventions. The system utilizes a bioelectric modulation mechanism which affects the systemic and local metabolic conditions by increasing the cell signaling and motility. This enhances therapeutic efficacy but also aligns treatment with the patient's glycemic status, making it particularly relevant for diabetic care[38-40].

Utilizing eMedica's VCF (Controlled Frequency Induction) adjuvant protocol in the management of diabetes revolves around insight to restore bioelectrical integrity at the cellular level, which is becomingly widely accepted as an integral yet published overlooked mechanism of metabolic derangement. Chronic hyperglycemia in diabetic state enhances mitochondrial dysfunction and oxidative stress, leading to membrane depolarization that inhibits insulin receptor signaling and downstream glucose uptake. Electrically stimulating specific regions of the body via VCF is intended to restore a healthy transmembrane potential maximizing insulin receptor conformational readiness, improving intracellular signaling function. Generating ATP, but targeting crucial pathophysiological substrates to work on mitochondria by controlled electrical inputs of low intensity over time stabilizes activity in the electron transport chain while reducing unnecessary turnover inducing excess free [Figure 1 and 2].

By lowering oxidative stress this directly impacts one of the key culprits behind insulin resistance. Moreover, the enhanced bioelectrical environment sensitizes cells to insulin medication by promoting GLUT4 glucose transporters' activation and translocation from intracellular compartments to the cell membrane, precisely where they can function to effectively uptake glucose into muscle/adipose tissues. By synchronizing these cellular contributions to glucose responsibility, the VCF procedure supplies a physiologic background for conventional antidiabetic medications (e.g., insulin sensitizers or secretagogues) to bring about improved action on their intended targets. Consequently, rather than possessing a pharmacotherapeutic substitution role per se, eMedica's method acts as an adjuvant treatment that favors the receptivity of the cells and is expressly in accordance with metabolic responsiveness, which could contribute to improving glycemic control in general and alleviating a major metabolic burden associated with diabetes: cellular stress.

Furthermore, the incorporation of smart intraoral devices allows for improved retention within periodontal pockets, prolonged drug action, and enhanced patient compliance. The antimicrobial formulations used in such systems are designed to target pathogenic oral microflora effectively while minimizing disruption to the normal oral microbiome.

Given these advancements, there is a growing need to clinically evaluate the effectiveness of such innovative systems in real-world settings. The present study is therefore designed to assess the impact of an eMedica-elctomagnetic modulation system on key clinical, biochemical, and microbiological parameters in patients with type 2 diabetes mellitus suffering from periodontal disease.

This study aims to bridge the gap between emerging drug delivery technologies and clinical periodontal practice, providing evidence for a more personalized, efficient, and patient-centric approach to managing oral health complications in diabetes.

Materials and Methods:

The present investigation was designed as a randomized, parallel-group clinical trial conducted over a duration of three months to evaluate the adjunctive efficacy of an eMedica-based localized drug delivery system in patients with type 2 diabetes mellitus and coexisting periodontal disease. A total of 60 participants were recruited following screening in accordance with predefined eligibility criteria. Patients aged between 35 and 65 years with a confirmed diagnosis of type 2 diabetes mellitus and clinical evidence of periodontal disease were included in the study. Individuals presenting with other systemic illnesses, a recent history of antibiotic therapy within the past three months, or any form of tobacco usage were excluded to minimize confounding variables that could influence periodontal healing or glycemic parameters.

Following enrollment, participants were randomly allocated into two equal groups using a computer-generated randomization protocol to ensure allocation concealment and reduce selection bias. Group A served as the control group and received conventional

periodontal therapy consisting of thorough scaling and root planing along with standard systemic diabetic management as prescribed by their physician. Group B, designated as the test group, received the same conventional therapy supplemented with the eMedica-based localized drug delivery system.

The eMedica system utilized in this study comprised a smart intraoral gel delivery device engineered to provide targeted application within periodontal pockets. The formulation incorporated a controlled-release antimicrobial agent designed to maintain therapeutic concentrations over an extended period, thereby enhancing local infection control. A distinctive feature of this system was its glucose-responsive drug release mechanism, which modulated the release kinetics in response to local glucose levels, thereby aligning antimicrobial delivery with the metabolic status of the patient.

Clinical evaluation was performed at baseline and at predetermined follow-up intervals throughout the study period. The primary clinical parameters assessed included the Gingival Index (GI) to evaluate gingival inflammation, Periodontal Pocket Depth (PPD) to determine the severity of periodontal destruction, and salivary glucose levels as a non-invasive indicator of glycemic status. All measurements were recorded by calibrated examiners to ensure consistency and reliability. The collected data were subjected to appropriate statistical analysis to compare intra-group and inter-group differences, thereby determining the clinical effectiveness of the eMedica-based intervention in improving periodontal and metabolic outcomes.

Clinical Parameters Assessed

- Gingival Index (GI)
- Periodontal Pocket Depth (PPD)
- Salivary glucose levels
- Microbial colony count

Statistical Analysis

Data were analyzed using SPSS software version 25. Paired and unpaired t-tests were applied. A p-value < 0.05 was considered statistically significant.

Ethical Clearance

The study was conducted following approval from the Institutional Ethics Committee and adhered to ethical standards.

Results

Clinical Outcomes

Table 1: Comparison of Clinical Parameters Between Groups

Parameter	Group A (Control)	Group B (eMedica)
Gingival Index	1.6 ± 0.2	0.9 ± 0.1
Pocket Depth Reduction	1.2 mm	2.3 mm
Microbial Load Reduction	35%	65%
Salivary Glucose Reduction	Mild	Significant

Graphical Representation

Table 1: Reduction in Gingival Index



Table 2: Pocket Depth Reduction



Table 3: Microbial Load Reduction (%)



Discussion

The present study demonstrates that the eMedica-based targeted drug delivery system significantly improves periodontal and biochemical parameters in patients with type 2 diabetes mellitus, thereby reinforcing the growing paradigm shift toward precision and stimulus-responsive therapeutics in oral healthcare.

One of the most notable findings of this study is the superior reduction in gingival inflammation and periodontal pocket depth in the eMedica group compared to conventional therapy. This can be attributed to the enhanced localization and sustained release of therapeutic agents within periodontal pockets. Conventional approaches often suffer from rapid drug clearance due to salivary flow and limited retention, resulting in subtherapeutic concentrations at the target site. In contrast, localized delivery systems particularly those incorporating nanotechnology and smart biomaterials have been shown to significantly improve drug bioavailability and therapeutic outcomes by maintaining effective concentrations for extended durations[32-35].

The marked reduction in microbial load observed in the test group further supports the efficacy of targeted antimicrobial delivery. Periodontal disease is fundamentally a biofilm-driven inflammatory condition, and disruption of pathogenic microbial communities is essential for disease control[12-15]. Recent advances in nanoparticle-based and bioresponsive drug delivery systems have demonstrated improved penetration into biofilms and selective targeting of periodontal pathogens, thereby enhancing antimicrobial efficacy while minimizing collateral damage to the commensal microbiota[32, 41-45].

A key innovative aspect of the eMedica system is its glucose-responsive drug release mechanism. Diabetes is characterized by fluctuating glycemic levels, which directly influence the severity of periodontal

inflammation[1-5]. The integration of glucose-sensitive delivery platforms allows for dynamic modulation of drug release in response to the local metabolic environment. Recent systematic reviews highlight that glucose-responsive drug delivery systems represent a transformative approach in diabetes management, enabling real-time adaptation of therapeutic dosing and improving disease control. This feature is particularly relevant in periodontal therapy, where local glucose levels in saliva and gingival crevicular fluid correlate with disease activity[17-21].

Furthermore, the observed improvement in salivary glucose levels in the test group suggests a potential bidirectional benefit. While improved glycemic control contributes to reduced periodontal inflammation, effective periodontal therapy has also been shown to improve systemic metabolic status by decreasing inflammatory mediators and insulin resistance. The findings of the present study support this interrelationship and indicate that targeted oral drug delivery may play a role in systemic disease modulation.

From a mechanistic perspective, the enhanced outcomes associated with eMedica can also be explained by principles of controlled and stimuli-responsive drug delivery. Emerging research in biomaterial-based systems including hydrogels, nanocarriers, and ferrogels demonstrates that controlled-release platforms can be engineered to respond to environmental triggers such as pH, enzymes, or glucose levels, ensuring precise spatiotemporal drug delivery. In periodontal pockets, where pH and inflammatory mediators are altered, such systems provide an additional layer of therapeutic specificity. Indeed, pH-responsive delivery systems have recently been explored for periodontal therapy, highlighting the feasibility of multi-stimuli responsive approaches in oral applications[46-50].

Another important consideration is patient compliance, which is often a limiting factor in chronic disease management. The sustained-release nature of eMedica reduces the need for frequent drug administration, thereby enhancing adherence to treatment protocols. This aligns with recent advancements in nanoliposomal and nano-based drug delivery systems, which emphasize prolonged drug action, reduced dosing frequency, and improved patient-centric care[32, 37, 41].

Despite these promising findings, certain limitations must be acknowledged. The relatively small sample size and short follow-up period restrict the generalizability of the results. Long-term studies with larger cohorts are necessary to evaluate the durability of clinical outcomes and the potential impact on systemic glycemic control. Additionally, while the current study demonstrates clinical efficacy, further investigation into the molecular and microbiological mechanisms underlying the observed improvements would provide deeper insight into the therapeutic potential of eMedica systems.

Future research should focus on integrating multi-responsive drug delivery platforms that combine glucose, pH, and inflammatory biomarkers for even greater precision in periodontal therapy. The incorporation of artificial intelligence and real-time biosensing technologies may further enhance the capabilities of such systems, enabling personalized and adaptive treatment strategies.

Overall, the findings of this study contribute to the growing body of evidence supporting the use of smart, targeted drug delivery systems in managing complex chronic conditions such as diabetes-associated periodontal disease. The eMedica platform represents a promising step toward the convergence of digital health, nanotechnology, and precision medicine in dentistry.

5. Conclusion

The eMedica-based targeted drug delivery system represents a promising advancement in the management of oral health complications in diabetes mellitus. It provides improved clinical outcomes, enhanced drug efficacy, and better patient compliance compared to conventional therapies. Further long-term studies with larger sample sizes are recommended to validate these findings.

6. Acknowledgment

The authors acknowledge the support of Rohera Healthcare Technologies Pvt. Ltd. and all participants involved in the study.

7. Conflict of Interest

The authors declare no conflict of interest.

References

1. Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Sci Rep. 2024 Mar 22;7(3):e2004. doi: 10.1002/hsr2.2004. PMID: 38524769; PMCID: PMC10958528.
2. The Lancet. Diabetes: a defining disease of the 21st century. Lancet. 2023 Jun 24;401(10394):2087. doi: 10.1016/S0140-6736(23)01296-5. PMID: 37355279.
3. Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022 Nov 19;400(10365):1803-1820. doi: 10.1016/S0140-6736(22)01655-5. Epub 2022 Nov 1. PMID: 36332637.
4. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023 Jul 15;402(10397):203-234. doi: 10.1016/S0140-6736(23)01301-6. Epub 2023 Jun 22. Erratum in: Lancet. 2023 Sep 30;402(10408):1132. doi:

10.1016/S0140-6736(23)02044-5. Erratum in: Lancet. 2025 Jan 18;405(10474):202. doi: 10.1016/S0140-6736(25)00053-4. PMID: 37356446; PMCID: PMC10364581.
5. Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS [Internet]. 10th ed. Brussels: International Diabetes Federation; 2021. PMID: 35914061.
6. Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: An overview. Avicenna J Med. 2020 Oct 13;10(4):174-188. doi: 10.4103/ajm.ajm_53_20. PMID: 33437689; PMCID: PMC7791288.
7. American Diabetes Association. 10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S105-S118. doi: 10.2337/dc18-S010. PMID: 29222381.
8. Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017 Apr 13;376(15):1407-1418. doi: 10.1056/NEJMoa1608664. PMID: 28402770.
9. Kahaly GJ, Hansen MP. Type 1 diabetes associated autoimmunity. Autoimmun Rev. 2016 Jul;15(7):644-8. doi: 10.1016/j.autrev.2016.02.017. Epub 2016 Feb 20. PMID: 26903475.
10. Hughes JW, Riddlesworth TD, DiMeglio LA, Miller KM, Rickels MR, McGill JB; T1D Exchange Clinic Network. Autoimmune Diseases in Children and Adults With Type 1 Diabetes From the T1D Exchange Clinic Registry. J Clin Endocrinol Metab. 2016 Dec;101(12):4931-4937. doi: 10.1210/jc.2016-2478. Epub 2016 Sep 27. PMID: 27676394; PMCID: PMC7530541.
11. Păunică I, Giurgiu M, Dumitriu AS, Păunică S, Pantea Stoian AM, Martu MA, Serafinceanu C. The Bidirectional Relationship between Periodontal Disease and Diabetes Mellitus-A Review. Diagnostics (Basel). 2023 Feb 11;13(4):681. doi: 10.3390/diagnostics13040681. PMID: 36832168; PMCID: PMC9954907.
12. Nazir MA. Prevalence of periodontal disease, its association with systemic diseases and prevention. Int J Health Sci (Qassim). 2017 Apr-Jun;11(2):72-80. PMID: 28539867; PMCID: PMC5426403.
13. Auerbacher M, Gebetsberger L, Kaisarly D, Schmidmaier R, Hickel R, Drey M. Oral health in patients with neurodegenerative and cerebrovascular disease: a retrospective study. Disabil Rehabil. 2023 Jul;45(14):2316-2324. doi: 10.1080/09638288.2022.2088866. Epub 2022 Jun 27. PMID: 35760764.
14. Zhou X, Zhang W, Liu X, Zhang W, Li Y. Interrelationship between diabetes and periodontitis: role of hyperlipidemia. Arch Oral Biol. 2015 Apr;60(4):667-74. doi: 10.1016/j.archoralbio.2014.11.008. Epub 2014 Nov 20. PMID: 25443979.
15. Preshaw PM, Bissett SM. Periodontitis and diabetes. Br Dent J. 2019 Oct;227(7):577-584. doi: 10.1038/s41415-019-0794-5. PMID: 31605062.
16. Zheng M, Wang C, Ali A, Shih YA, Xie Q, Guo C. Prevalence of periodontitis in people clinically diagnosed with diabetes mellitus: a meta-analysis of epidemiologic studies. Acta Diabetol. 2021 Oct;58(10):1307-1327. doi: 10.1007/s00592-021-01738-2. Epub 2021 May 24. PMID: 34028620.
17. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014 Feb;18(1):1-14. doi: 10.4196/kjpp.2014.18.1.1. Epub 2014 Feb 13. PMID: 24634591; PMCID: PMC3951818.
18. Forbes JM, Soldatos G, Thomas MC. Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes? Clin Biochem Rev. 2005 Nov;26(4):123-34. PMID: 16648883; PMCID: PMC1320176.
19. Jang C, Lim JH, Park CW, Cho YJ. Regulator of Calcineurin 1 Isoform 4 (RCAN1.4) Is Overexpressed in the Glomeruli of Diabetic Mice. Korean J Physiol Pharmacol. 2011 Oct;15(5):299-305. doi: 10.4196/kjpp.2011.15.5.299. Epub 2011 Oct 31. PMID: 22128263; PMCID: PMC3222800.
20. Khan N, Bakshi KS, Jaggi AS, Singh N. Ameliorative potential of spironolactone in diabetes induced hyperalgesia in mice. Yakugaku Zasshi. 2009 May;129(5):593-9. doi: 10.1248/yakushi.129.593. PMID: 19420890.
21. Bolchis V, Jumanca D, Dumitrescu R, Balean O, Toderas NA, Popescu S, Marcu A, Marian C, Galuscan A. Glycemic Control, Inflammatory Mediators, and Periodontal Health: A Cross-Sectional Study in Patients with Diabetes. J Clin Med. 2025 Apr 21;14(8):2847. doi: 10.3390/jcm14082847. PMID: 40283677; PMCID: PMC12028111.
22. Costa PP, Trevisan GL, Macedo GO, Palioto DB, Souza SL, Grisi MF, Novaes AB Jr, Taba M Jr. Salivary interleukin-6, matrix metalloproteinase-8, and osteoprotegerin in patients with periodontitis and diabetes. J Periodontol. 2010 Mar;81(3):384-91. doi: 10.1902/jop.2009.090510. PMID: 20192865.
23. Techatanawat S, Surarit R, Chairatvit K, Khovidhunkit W, Roytrakul S, Thanakun S, Kobayashi H, Khovidhunkit SP, Izumi Y. Salivary and serum interleukin-17A and interleukin-18 levels in patients with type 2 diabetes mellitus with and without periodontitis.

PLoS One. 2020 Feb 13;15(2):e0228921. doi: 10.1371/journal.pone.0228921. Erratum in: PLoS One. 2026 Mar 17;21(3):e0345302. doi: 10.1371/journal.pone.0345302. PMID: 32053656; PMCID: PMC7018084.

24. Santos VR, Lima JA, Gonçalves TE, Bastos MF, Figueiredo LC, Shibli JA, Duarte PM. Receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in sites of chronic periodontitis of subjects with poorly and well-controlled type 2 diabetes. J Periodontol. 2010 Oct;81(10):1455-65. doi: 10.1902/jop.2010.100125. PMID: 20476881.
25. Kardeşler L, Biyikoğlu B, Cetinkalp S, Pitkala M, Sorsa T, Buduneli N. Crevicular fluid matrix metalloproteinase-8, -13, and TIMP-1 levels in type 2 diabetics. Oral Dis. 2010 Jul;16(5):476-81. doi: 10.1111/j.1601-0825.2010.01659.x. Epub 2010 Mar 9. PMID: 20233316.
26. Wu SY, Wu CY, Lin LY, Chen YH, Huang HY, Lai YL, Lee SY. Systemic antibiotics adjuvants to scaling and root planing in type 2 diabetic and periodontitis individuals: Systematic review with network meta-analysis. Jpn Dent Sci Rev. 2023 Dec;59:167-178. doi: 10.1016/j.jdsr.2023.06.001. Epub 2023 Jun 18. PMID: 38152384; PMCID: PMC10751746.
27. Smiley CJ, Tracy SL, Abt E, Michalowicz BS, John MT, Gunsolley J, Cobb CM, Rossmann J, Harrel SK, Forrest JL, Hujoel PP, Noraian KW, Greenwell H, Frantsve-Hawley J, Estrich C, Hanson N. Systematic review and meta-analysis on the nonsurgical treatment of chronic periodontitis by means of scaling and root planing with or without adjuncts. J Am Dent Assoc. 2015 Jul;146(7):508-24.e5. doi: 10.1016/j.adaj.2015.01.028. PMID: 26113099.
28. Eberhard J, Jepsen S, Jervøe-Storm PM, Needleman I, Worthington HV. Full-mouth treatment modalities (within 24 hours) for chronic periodontitis in adults. Cochrane Database Syst Rev. 2015 Apr 17;2015(4):CD004622. doi: 10.1002/14651858.CD004622.pub3. Update in: Cochrane Database Syst Rev. 2022 Jun 28;6:CD004622. doi: 10.1002/14651858.CD004622.pub4. PMID: 25884249; PMCID: PMC8687876.
29. Nambiar S, Malothu S, Karmakar S, Varkey A, Chandra D, Chava VK. Comparison of Ozonated Olive Oil and Chlorhexidine Gel as an Adjunct to Nonsurgical Periodontal Therapy for the Treatment of Chronic Periodontitis: A Randomized Controlled Clinical Trial. J Pharm Bioallied Sci. 2022 Jul;14(Suppl 1):S94-S98. doi: 10.4103/jpbs.jpbs_565_21. Epub 2022 Jul 13. PMID: 36110593; PMCID: PMC9469280.
30. Jia L, Jia J, Xie M, Zhang X, Li T, Shi L, Shi H, Zhang X. Clinical attachment level gain of lasers in scaling and root planing of chronic periodontitis: a network meta-analysis of randomized controlled clinical trials. Lasers Med Sci. 2020 Mar;35(2):473-485. doi: 10.1007/s10103-019-02875-5. Epub 2019 Nov 5. PMID: 31691054.
31. Soundarajan S, Rajasekar A. Comparative evaluation of combined efficacy of methylene blue mediated antimicrobial photodynamic therapy (a-PDT) using 660 nm diode laser versus Erbium-chromium-yttrium-scandium-gallium-garnet (Er, Cr: YSGG) laser as an adjunct to scaling and root planing on clinical parameters in supportive periodontal therapy: A randomized split-mouth trial. Photodiagnosis Photodyn Ther. 2022 Sep;39:102971. doi: 10.1016/j.pdpdt.2022.102971. Epub 2022 Jun 20. PMID: 35738551.
32. Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, Okoroafor CC, Eze SC, Kalu OL, Odoh EC, Nwadike UG, Ogbodo JO, Umeh BU, Ossai EC, Nwanguma BC. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023 Jun 24;9(6):e17488. doi: 10.1016/j.heliyon.2023.e17488. PMID: 37416680; PMCID: PMC10320272.
33. Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021 Sep;5(9):951-967. doi: 10.1038/s41551-021-00698-w. Epub 2021 Apr 1. PMID: 33795852.
34. Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in Oral Drug Delivery. Front Pharmacol. 2021 Feb 19;12:618411. doi: 10.3389/fphar.2021.618411. PMID: 33679401; PMCID: PMC7933596.
35. Sharma P, Gajula K, Dingari NN, Gupta R, Gopal S, Rai B, Iacocca RG. Subcutaneous Drug Delivery: A Review of the State-of-the-Art Modeling and Experimental Techniques. J Biomech Eng. 2023 Feb 1;145(2):020801. doi: 10.1115/1.4055758. PMID: 36149008.
36. Badkar AV, Gandhi RB, Davis SP, LaBarre MJ. Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements. Drug Des Devel Ther. 2021 Jan 13;15:159-170. doi: 10.2147/DDDT.S287323. PMID: 33469268; PMCID: PMC7812053.
37. Gholap AD, Uddin MJ, Faiyazuddin M, Omri A, Gowri S, Khalid M. Advances in artificial intelligence for drug delivery and development: A comprehensive review. Comput Biol Med. 2024 Aug;178:108702. doi: 10.1016/j.compbiomed.2024.108702. Epub 2024 Jun 7. PMID: 38878397.
38. Rohera H, Nagpal D, Jambhulkar M. Electromagnetic Cell Current Modulation As Adjunctive Therapy in HIV: A Review. Cureus. 2025 Sep 19;17(9):e92697. doi:

10.7759/cureus.92697. PMID: 41116920; PMCID: PMC12535686.
39. Rohera H, Nagpal DJ. Evaluating the efficacy of microcurrent infusion technology through eMedica in the management of gout: An analysis of patient outcomes. Indian J Med Sci. 2026;78:80-4. doi: 10.25259/IJMS_287_2024.
40. Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis Rheumatol. 2018 Nov;70(11):1702-1709. doi: 10.1002/art.40583. Erratum in: Arthritis Rheumatol. 2018 Dec;70(12):2086. doi: 10.1002/art.40781. PMID: 29869840; PMCID: PMC6203619.
41. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018 Sep 19;16(1):71. doi: 10.1186/s12951-018-0392-8. PMID: 30231877; PMCID: PMC6145203.
42. Choi V, Carugo D, Stride E. Repurposing antimicrobials with ultrasound-triggered nanoscale systems for targeted biofilm drug delivery. NPJ Antimicrob Resist. 2025 Apr 1;3(1):22. doi: 10.1038/s44259-025-00086-3. PMID: 40169915; PMCID: PMC11962098.
43. Lai L, Han X, Tang Y, Zhou J, Cui W. Advances in ultrasound-assisted drug delivery and clinical application. Ultrason Sonochem. 2026 Jan;124:107557. doi: 10.1016/j.ultsonch.2025.107557. Epub 2025 Sep 11. PMID: 41380545; PMCID: PMC12752531.
44. Ahmed S, Ahmed MZ, Rafique S, Almasoudi SE, Shah M, Jalil NAC, Ojha SC. Recent Approaches for Downplaying Antibiotic Resistance: Molecular Mechanisms. Biomed Res Int. 2023 Jan 23;2023:5250040. doi: 10.1155/2023/5250040. PMID: 36726844; PMCID: PMC9886476.
45. Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W, Hu Y, Shi J. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther. 2025 Mar 5;10(1):74. doi: 10.1038/s41392-024-02107-5. PMID: 40038239; PMCID: PMC11880366.
46. Lu P, Ruan D, Huang M, Tian M, Zhu K, Gan Z, Xiao Z. Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions. Signal Transduct Target Ther. 2024 Jul 1;9(1):166. doi: 10.1038/s41392-024-01852-x. PMID: 38945949; PMCID: PMC11214942.
47. Lau HK, Kiick KL. Opportunities for multicomponent hybrid hydrogels in biomedical applications. Biomacromolecules. 2015 Jan 12;16(1):28-42. doi: 10.1021/bm501361c. Epub 2014 Dec 10. PMID: 25426888; PMCID: PMC4294583.
48. Maity S, Deb VK, Mondal S, Chakraborty A, Pramanick K, Adhikari S. Leveraging supramolecular systems in biomedical breakthroughs. Biofactors. 2025 Jan-Feb;51(1):e70005. doi: 10.1002/biof.70005. PMID: 39902766.
49. Bodnár K, Fehér P, Ujhelyi Z, Haimhoffer Á, Papp B, Sinka D, Freytag C, Fidrus E, Szarka K, Kardos G, Nacsa F, Bácskay I, Józsa L. Formulation and Testing of Alginate Microbeads Containing Salvia officinalis Extract and Prebiotics. Pharmaceutics. 2025 Oct 8;17(10):1308. doi: 10.3390/pharmaceutics17101308. PMID: 41155945; PMCID: PMC12566799.
50. Cavallo C, Desando G, D'Alessandro M, Grigolo B, Roseti L. Recent Evidence for Orthobiologics bined with Hydrogels for Joint Tissue Regeneration: Focus on Osteoarthritis. Gels. 2025 Jul 17;11(7):551. doi: 10.3390/gels11070551. PMID: 40710712; PMCID: PMC12294168.

Figures

Figure 1:

eMedica Device



Figure 2: Patient using the eMedica device as a routine daily schedule.